Intranasal anthrax vaccine - ProStrakan
Alternative Names: Intranasal anthraxLatest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator Archimedes Pharma
- Developer Kyowa Kirin International; Takeda
- Class Anthrax vaccines; Bacterial vaccines
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Anthrax
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Anthrax in United Kingdom (Intranasal)
- 05 Aug 2014 Archimedes Pharma has been acquired by ProStrakan
- 05 Oct 2012 LigoCyte Pharmaceuticals has been acquired and merged into Takeda